Oseltamivir and abnormal behavior

Epidemiology

Volumn 21, Issue 6, 2010, Pages 915-916

  Peng, Michael M ^a   Robinson, Noah Jamie ^b  

^a Hoffman La Roache Inc   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ABNORMAL BEHAVIOR; DISEASE EXACERBATION; FOLLOW UP; HUMAN; INFLUENZA; LETTER; MENTAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIVIRAL AGENTS; FOLLOW-UP STUDIES; HUMANS; MENTAL DISORDERS; OSELTAMIVIR; RISK FACTORS;

EID: 77958480462     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181f3544c     Document Type: Letter

References (4)

1. Hirota Y. Survey research on the emergence of influenza-associated symptoms: 2007/2008 research subteam report. Research on evidence and methods for improving vaccine usefulness. Tokyo: MHLW Scientific Research Fund Pharmaceutical and Medical Device Regulatory Science Integrated Research Initiative; March 2009.
2. Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology. 2009;20:619-621.
3. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79-89.
4. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31: 1097-1114.